HOW MUTATIONS IN THE HIV-1 3’-POLYPURINE TRACT CONFER DOLUTEGRAVIR RESISTANCE
The integrase strand-transfer inhibitor (INSTI) dolutegravir (DTG) is widely applied in combination antiretroviral therapy for HIV-infected individuals. Resistance to DTG is usually associated with mutations in the integrase gene, but a previous in vitro HIV selection study identified a mutation in the 3′-polypurine tract (3’PPT) that reduced DTG sensitivity (Malet mBio 2017), and mutation of…